← Back to Screener
PharmaCyte Biotech, Inc. Common Stock (PMCB)
Price$0.70
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-17.44%
Price vs S&P 500 (4W)-7.37%
VGM Score40.77
Market Capitalization$7.51M
P/E Ratio (Annual)0.25x
All Metrics
Book Value / Share (Quarterly)$3.67
P/TBV (Annual)0.17x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.45
Price vs S&P 500 (YTD)-11.47%
Gross Margin (TTM)81.70%
Net Profit Margin (TTM)-4184.21%
EPS (TTM)$-0.53
10-Day Avg Trading Volume0.19M
EPS Excl Extra (TTM)$-0.53
EPS (Annual)$4.18
ROI (Annual)59.08%
Gross Margin (Annual)0.00%
Net Profit Margin (5Y Avg)-4635.63%
Cash / Share (Quarterly)$1.91
P/E Normalized (Annual)0.25x
ROA (Last FY)55.57%
EBITD / Share (TTM)$-0.71
ROE (5Y Avg)-0.78%
Operating Margin (TTM)-3469.42%
Cash Flow / Share (Annual)$-0.44
P/B Ratio0.19x
P/B Ratio (Quarterly)0.21x
Net Income / Employee (Annual)$15,328,000
EV / Revenue (TTM)-317.06x
Net Interest Coverage (TTM)-1361.50x
ROA (TTM)-6.19%
EV / EBITDA (TTM)-6.47x
EPS Incl Extra (Annual)$4.18
Current Ratio (Annual)7.68x
Quick Ratio (Quarterly)12.24x
3-Month Avg Trading Volume0.18M
52-Week Price Return-37.22%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.53
P/S Ratio (Annual)751.50x
Asset Turnover (Annual)0.00x
52-Week High$1.51
Operating Margin (5Y Avg)-4103.67%
EPS Excl Extra (Annual)$4.18
Tangible BV CAGR (5Y)100.85%
26-Week Price Return-9.51%
Quick Ratio (Annual)7.60x
13-Week Price Return7.58%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)12.33x
Enterprise Value$-12.65M
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)10.54%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.33x
Pretax Margin (Annual)-16000.00%
Cash / Share (Annual)$2.72
3-Month Return Std Dev91.79%
Gross Margin (5Y Avg)37.52%
Net Income / Employee (TTM)$-1,640,800
ROE (Last FY)59.08%
Net Interest Coverage (Annual)-0.15x
EPS Basic Excl Extra (Annual)$4.18
Receivables Turnover (TTM)1.96x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.53
Receivables Turnover (Annual)26.00x
ROI (TTM)-7.66%
P/S Ratio (TTM)188.34x
Pretax Margin (5Y Avg)-4635.63%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.41
Price vs S&P 500 (52W)-61.59%
Year-to-Date Return-3.31%
5-Day Price Return-12.51%
EPS Normalized (Annual)$4.18
ROA (5Y Avg)-0.48%
Net Profit Margin (Annual)-16000.00%
Month-to-Date Return-16.11%
Cash Flow / Share (TTM)$-0.21
EBITD / Share (Annual)$-0.60
Operating Margin (Annual)-14500.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-0.78%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.53
P/TBV (Quarterly)0.22x
P/B Ratio (Annual)0.16x
Inventory Turnover (TTM)5.10x
Pretax Margin (TTM)-4184.21%
Book Value / Share (Annual)$7.64
Price vs S&P 500 (13W)-0.68%
Beta0.57x
Revenue / Share (TTM)$0.00
ROE (TTM)-7.66%
52-Week Low$0.63
mGradeC
vgmGradeC
Show chart for
Analyst Recommendations
Nov 2022
Dec 2022
Jan 2023
Feb 2023
2.17
2.17
2.17
2.17
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PMCBPharmaCyte Biotech, Inc. Common Stock | — | — | C | $0.70 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
PharmaCyte Biotech is a clinical-stage biotechnology company developing cellular therapies for cancer and diabetes using its proprietary Cell-in-a-Box technology, which encapsulates live cells to deliver cancer-killing drugs directly at tumor sites. The platform is designed to protect therapeutic cells from the immune system while enabling localized drug delivery, with current development efforts focused on inoperable pancreatic cancer and other solid tumors. The company is leveraging this platform technology to address multiple cancer indications and diabetes.